

Theresa A Mcdonagh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7806107/theresa-a-mcdonagh-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83

papers

7,017

citations

30

h-index

83

g-index

101

ext. papers

12,277

ext. citations

8.4

avg, IF

5.29

L-index

#	Paper	IF	Citations
83	Implementation of the Mental Capacity Act: a national observational study comparing resultant trends in place of death for older heart failure decedents with or without comorbid dementia.. <i>BMC Medicine</i> , 2022 , 20, 30	11.4	
82	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology.. <i>European Journal of Heart Failure</i> , 2022 , 24, 132-142	12.3	4
81	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA). <i>European Journal of Heart Failure</i> , 2022 , 24, 1-131	12.3	50
80	Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction.. <i>International Journal of Cardiovascular Imaging</i> , 2022 , 1	2.5	0
79	Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan. <i>Journal of Cardiovascular Medicine</i> , 2022 , 23, 37-41	1.9	1
78	Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.. <i>Circulation</i> , 2022 , 145, 1123-1139	16.7	13
77	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2976	5.1	1
76	Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	9
75	A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	4
74	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021 ,	9.5	17
73	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021 ,	9.5	29
72	New horizons in cardiogeriatrics: geriatricians and heart failure care-the custard in the tart, not the icing on the cake. <i>Age and Ageing</i> , 2021 , 50, 1064-1068	3	1
71	Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 378-387	4.6	14
70	Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. <i>American Journal of Cardiology</i> , 2021 , 152, 138-145	3	0
69	Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy.. <i>British Journal of Psychiatry</i> , 2021 , 219, 644-651	5.4	5
68	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular Round Table. <i>Cardiovascular Research</i> , 2021 , 117, 1248-1256	9.9	1
67	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	28

66	ST2 in patients with severe aortic stenosis and heart failure. <i>Cardiology Journal</i> , 2021 , 28, 129-135	1.4	1
65	Impact of the COVID-19 pandemic on in-hospital mortality in cardiovascular disease: a meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	5
64	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
63	Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021 , 27, 1477-1482	50.5	17
62	Long-term outcomes after heart failure hospitalization during the COVID-19 pandemic: a multisite report from heart failure referral centers in London. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
61	The Ten Commandments of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 ,	9.5	8
60	The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. <i>European Journal of Heart Failure</i> , 2020 , 22, 978-984	12.3	84
59	Cardiology after COVID-19: Quo Vademus?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 208-209	4.6	2
58	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020 , 7, 2098-2112	3.7	14
57	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1378-1389	12.3	32
56	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1424-1437	12.3	13
55	The year in cardiology 2019: heart failure. <i>Revista Romana De Cardiologie</i> , 2020 , 30, 185-204	0.1	
54	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 92-102	12.3	35
53	The year in cardiology: heart failure. <i>European Heart Journal</i> , 2020 , 41, 1232-1248	9.5	7
52	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. <i>JACC: Heart Failure</i> , 2020 , 8, 212-222	7.9	31
51	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020 , 396, 1895-1904	40	162
50	Palliative Care in Acute Heart Failure. <i>Current Heart Failure Reports</i> , 2020 , 17, 424-437	2.8	2
49	Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London. <i>European Journal of Heart Failure</i> , 2020 , 22, 2219-2224	12.3	46

48	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 272-285	12.3	99
47	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 1169-1186	12.3	325
46	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019 , 21, 1383-1397	12.3	20
45	Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 461-470	3.9	31
44	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019 , 40, 87-165	9.5	2408
43	Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2019 , 139, 2386-2398	16.7	58
42	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1651-1658	12.3	26
41	Less invasive ventricular reconstruction for ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1638-1650	12.3	23
40	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264
39	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 474-480	12.3	15
38	A cost effectiveness study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP threshold in patients with clinically suspected heart failure at our institution. <i>International Journal of Cardiology</i> , 2018 , 257, 131-136	3.2	0
37	B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. <i>Systematic Reviews</i> , 2018 , 7, 112	3	21
36	Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>Heart</i> , 2018 , 104, 407-415	5.1	75
35	6 Comparing echocardiography and cardiac magnetic resonance measures of ejection fraction: implications for HFMRF research 2018 ,		3
34	Comparison of the Diagnostic Accuracy of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients 80 Years of Age with Heart Failure. <i>American Journal of Cardiology</i> , 2018 , 122, 2075-2079	3	3
33	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018 , 20, 1664-1672	12.3	54
32	Mortality after admission for heart failure in the UK compared with Japan. <i>Open Heart</i> , 2018 , 5, e0008113		6
31	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 1505-1535	12.3	285

30	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2018 , 6, 517-526	7.9	37
29	Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. <i>European Journal of Heart Failure</i> , 2018 , 20, 1179-1190	12.3	12
28	Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). <i>American Journal of Cardiology</i> , 2017 , 119, 440-444	3	16
27	Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. <i>Heart</i> , 2017 , 103, 55-62	5.1	11
26	MICE or NICE? An economic evaluation of clinical decision rules in the diagnosis of heart failure in primary care. <i>International Journal of Cardiology</i> , 2017 , 241, 255-261	3.2	5
25	Identifying patients with less potential to benefit from implantable cardioverter-defibrillator therapy: comparison of the performance of four risk scoring systems. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017 , 49, 181-189	2.4	1
24	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2186-2200	15.1	107
23	Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. <i>Health Technology Assessment</i> , 2017 , 21, 1-150	4.4	17
22	The healthcare costs of heart failure during the last five years of life: A retrospective cohort study. <i>International Journal of Cardiology</i> , 2016 , 224, 132-138	3.2	28
21	Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum. <i>European Journal of Heart Failure</i> , 2016 , 18, 736-43	12.3	33
20	Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2016 , 37, 1419-27	9.5	122
19	Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study. <i>International Journal of Cardiology</i> , 2016 , 207, 279-81	3.2	10
18	Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring. <i>American Journal of Cardiology</i> , 2016 , 118, 95-8	3	18
17	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016 , 18, 482-9	12.3	49
16	Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?. <i>European Journal of Heart Failure</i> , 2015 , 17, 248-62	12.3	85
15	Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. <i>International Journal of Cardiology</i> , 2015 , 178, 284-91	3.2	23
14	43 Acute Heart Failure: Where did We Get Wrong?. <i>Heart</i> , 2015 , 101, A25.1-A25	5.1	
13	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015 , 36, 657-68	9.5	59 ¹

12	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015 , <i>17</i> , 544-53	12.3	236
11	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. <i>European Heart Journal</i> , 2015 , <i>36</i> , 1958-66	9.5	75
10	Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. <i>European Heart Journal Cardiovascular Imaging</i> , 2015 , <i>16</i> , 147-53	4.1	32
9	Chemotherapy-related Cardiomyopathy. <i>European Cardiology Review</i> , 2015 , <i>10</i> , 19-24	3.9	8
8	Heart failure association of the European society of cardiology specialist heart failure curriculum. <i>European Journal of Heart Failure</i> , 2014 , <i>16</i> , 151-62	12.3	35
7	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014 , <i>1</i> , 52-58	3.7	31
6	Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: a meta-analysis. <i>Heart Rhythm</i> , 2014 , <i>11</i> , 828-35	6.7	29
5	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency 2014 , <i>1</i> , 52		1
4	The Year in Cardiology 2012: heart failure. <i>European Heart Journal</i> , 2013 , <i>34</i> , 499-502	9.5	
3	The national heart failure audit for England and Wales 2008-2009. <i>Heart</i> , 2011 , <i>97</i> , 876-86	5.1	100
2	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. <i>European Journal of Heart Failure</i> , 2011 , <i>13</i> , 1253-60	12.3	27
1	Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. <i>European Heart Journal</i> , 2007 , <i>28</i> , 3027-33	9.5	27